|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
1966
|
|
gptkbp:ATCCode
|
gptkb:N04BB01
|
|
gptkbp:availableOn
|
gptkb:tablet
capsule
oral syrup
|
|
gptkbp:CASNumber
|
gptkb:768-94-5
|
|
gptkbp:category
|
gptkb:World_Health_Organization_essential_medicines
|
|
gptkbp:chemical_structure
|
adamantane derivative
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Du_Pont
|
|
gptkbp:discoveredBy
|
1960s
|
|
gptkbp:drugClass
|
antiparkinsonian agent
adamantane derivative
antiviral
|
|
gptkbp:eliminationHalfLife
|
10-14 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
gptkb:C10H17N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
amantadine
|
|
gptkbp:interactsWith
|
CNS stimulants
anticholinergic drugs
diuretics
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonist
antiviral (M2 proton channel inhibitor)
dopamine release enhancer
|
|
gptkbp:meltingPoint
|
110-115°C
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:notEffectiveAgainst
|
gptkb:influenza_B
|
|
gptkbp:overdoseSymptoms
|
gptkb:arrhythmia
seizures
hallucinations
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
2130
|
|
gptkbp:resistance_issue
|
influenza A virus resistance common
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
insomnia
livedo reticularis
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:synonym
|
gptkb:1-adamantanamine
gptkb:Symmetrel
|
|
gptkbp:UNII
|
U7DD958KAP
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
gptkb:influenza_A
drug-induced extrapyramidal symptoms
|
|
gptkbp:bfsParent
|
gptkb:memantine
|
|
gptkbp:bfsLayer
|
5
|